Below are the most recent publications written about "Biphenyl Compounds" by people in Profiles.
-
Nathaniel S, McGinty S, Witman MA, Edwards DG, Farquhar WB, Hosmane V, Wenner MM. A new lead: Sacubitril-valsartan's unique benefit in HFrEF could lie with sympathoinhibition. Auton Neurosci. 2022 03; 238:102949.
-
Kim DH, Chien FJ, Eisen HJ. Pharmacologic Management for Heart Failure and Emerging Therapies. Curr Cardiol Rep. 2017 08 24; 19(10):94.
-
Patsenker E, Chicca A, Petrucci V, Moghadamrad S, de Gottardi A, Hampe J, Gertsch J, Semmo N, Stickel F. 4-O'-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice. J Mol Med (Berl). 2017 10; 95(10):1077-1089.
-
Schultz TC, Valenzano JP, Verzella JL, Umland EM. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis. Womens Health (Lond). 2015 Nov; 11(6):805-14.
-
Acharya NK, Levin EC, Clifford PM, Han M, Tourtellotte R, Chamberlain D, Pollaro M, Coretti NJ, Kosciuk MC, Nagele EP, Demarshall C, Freeman T, Shi Y, Guan C, Macphee CH, Wilensky RL, Nagele RG. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis. 2013; 35(1):179-98.
-
Nagano JM, Hsu KL, Whitby LR, Niphakis MJ, Speers AE, Brown SJ, Spicer T, Fernandez-Vega V, Ferguson J, Hodder P, Srinivasan P, Gonzalez TD, Rosen H, Bahnson BJ, Cravatt BF. Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2). Bioorg Med Chem Lett. 2013 Feb 01; 23(3):839-43.
-
Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch C. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol. 2012 Jun; 59(6):539-46.
-
Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray JJ, Solomon SD. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012 May 15; 59(20):1785-95.
-
Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J. 2011 Nov; 162(5):900-6.
-
Westlake BC, Brennaman MK, Concepcion JJ, Paul JJ, Bettis SE, Hampton SD, Miller SA, Lebedeva NV, Forbes MD, Moran AM, Meyer TJ, Papanikolas JM. Concerted electron-proton transfer in the optical excitation of hydrogen-bonded dyes. Proc Natl Acad Sci U S A. 2011 May 24; 108(21):8554-8.